Last reviewed · How we verify

BION-1301 — Competitive Intelligence Brief

BION-1301 (BION-1301) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR4 inhibitor monoclonal antibody. Area: Oncology.

phase 3 FGFR4 inhibitor monoclonal antibody FGFR4 (Fibroblast Growth Factor Receptor 4) Oncology Biologic Live · refreshed every 30 min

Target snapshot

BION-1301 (BION-1301) — Chinook Therapeutics, Inc.. BION-1301 is a monoclonal antibody that targets and inhibits FGFR4 (fibroblast growth factor receptor 4) to reduce hepatocellular carcinoma cell growth and survival.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BION-1301 TARGET BION-1301 Chinook Therapeutics, Inc. phase 3 FGFR4 inhibitor monoclonal antibody FGFR4 (Fibroblast Growth Factor Receptor 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR4 inhibitor monoclonal antibody class)

  1. Chinook Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BION-1301 — Competitive Intelligence Brief. https://druglandscape.com/ci/bion-1301. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: